8-K: Avant Technologies Forms Insulinova Joint Venture

Avant Technologies Inc. has formed a 50/50 joint venture, Insulinova Inc., with biotech firm SGAustria Pte. Ltd. to develop diabetes treatments, committing up to $1.5 million in initial capital.

Summary

• Avant Technologies Inc. (AVAI) and SGAustria Pte. Ltd. (Austrianova) entered into a Joint Venture and License Agreement on November 1, 2025, to form Insulinova, Inc.
• Insulinova, Inc. will be a 50/50 owned joint venture, with its purpose being to develop, use, and commercialize treatments for Diabetes exclusively using encapsulated insulin-producing cells.
• Austrianova contributes its proprietary cell encapsulation technology, intellectual property, know-how, and resources to Insulinova.
• AVAI will contribute up to $1.5 million USD in capital and resources for Insulinova's formation and operation for the next eighteen (18) months.
• AVAI will also use its best efforts to assist in arranging additional funding as needed for Insulinova.
• The agreement replaces and supersedes a previous Joint Venture & License Agreement from September 19, 2025, which was retracted on September 24, 2025.
• Insulinova will have 4,500,000 authorized shares of Common Stock with a par value of US $0.001 per share.
• AVAI and Austrianova will each hold 1,500,000 shares of Common Stock, representing 50% ownership each.
• AVAI has the option to provide an additional $8.5 million follow-up financing (Loan) to Insulinova for further development and clinical testing.
• The collateral for this potential $8.5 million loan will only be Insulinova's cash flow, excluding Austrianova's intellectual property.
• If AVAI chooses not to provide the follow-up financing, Austrianova will be free to proceed with further development of the encapsulated cell product outside of Insulinova, retaining rights to its IP.
• Upon further investment beyond the initial $10 million USD (AVAI's $1.5 million equity + $8.5 million potential loan), the $8.5 million loan will be repaid to AVAI.
• Beyond the $10 million investment mark, use of Austrianova's encapsulation technology will incur license and milestone payments.
• Insulinova will be managed by a Board of Directors with one representative from AVAI and one from Austrianova.
• Kenn Kerr has been appointed as the Chief Executive Officer of Insulinova, and Walter H. Gnzburg, Ph.D., will initially serve as Chairman of the Board.
• The agreement is effective November 1, 2025, for an initial term of five years, automatically renewed annually.

Sentiment

Score: 7

Explanation: The formation of a joint venture in a high-potential area like diabetes treatment with a scientifically strong partner is a positive strategic move. However, the previous retraction of a similar agreement and the optional nature of significant future funding from AVAI introduce some caution.

Positives

• Formation of a joint venture (Insulinova, Inc.) targets the high-potential diabetes treatment market using advanced cell encapsulation technology.
• Austrianova brings significant scientific expertise, backed by over 50 international peer-reviewed publications and contracts with leading pharmaceutical and biotech companies.
• AVAI commits substantial initial funding of up to $1.5 million for 18 months of Insulinova's operations, demonstrating financial backing.
• Potential for significant follow-up financing of $8.5 million from AVAI for critical clinical trials and regulatory work, accelerating product development.
• Clear governance structure with 50/50 ownership and defined board representation ensures shared control and strategic alignment.
• Appointment of experienced leadership (CEO Kenn Kerr and Chairman Walter H. Gnzburg, Ph.D.) for Insulinova provides management stability.
• Insulinova receives an exclusive worldwide license to Austrianova's cell encapsulation technology for diabetes treatment.

Negatives

• The new agreement replaces a previous joint venture agreement from September 19, 2025, which was retracted on September 24, 2025, indicating prior instability or changes in strategic direction.
• AVAI's commitment to the $8.5 million follow-up financing is optional, contingent on "AVAIs choosing to move forward on future projects," introducing uncertainty regarding long-term funding.
• If AVAI does not provide the follow-up financing, Austrianova can develop the encapsulated cell product outside Insulinova, potentially limiting Insulinova's future scope and value.
• The initial $1.5 million funding from AVAI is for 18 months, after which additional capital will be required, which may necessitate further capital raises.
• The formal establishment of Insulinova, Inc. is projected to occur "in the next twelve months," meaning the company is not yet fully operational.
• The collateral for the potential $8.5 million loan is limited to Insulinova's cash flow, excluding Austrianova's core intellectual property, which might limit AVAI's recourse in case of venture failure.

Risks

• Reliance on AVAI for future funding beyond the initial $1.5 million, with the $8.5 million loan being optional and not guaranteed.
• Risk of Austrianova developing the encapsulated cell product outside Insulinova if AVAI does not provide the follow-up financing, potentially diminishing Insulinova's value and exclusive rights.
• The success of Insulinova is contingent on the successful development, clinical validation, and commercialization of treatments for Diabetes using encapsulated insulin-producing cells, which is a complex, lengthy, and high-risk endeavor inherent in biotech.
• Significant regulatory approval risks exist for clinical trials and product registration in various jurisdictions globally.
• Potential for deadlock in decision-making at the Board level, requiring third-party mediation, which could slow progress.
• The previous retraction of a similar JV agreement suggests potential for future disagreements or changes in strategic direction.
• The company Insulinova, Inc. is not yet formally established, introducing an initial setup and operational risk.

Future Outlook

The joint venture, Insulinova, Inc., aims to develop, use, and commercialize treatments for Diabetes using encapsulated insulin-producing cells globally. AVAI is committed to initial funding for 18 months and may provide substantial follow-up financing for clinical trials and regulatory work. The formal establishment of Insulinova, Inc. is expected within the next twelve months, with the agreement having an initial term of five years, automatically renewed annually.

Management Comments

• "These statements are based on current expectations and assumptions and involve risks and uncertainties. Actual results may differ materially from those described in the forward-looking statements."
• "The Company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date hereof, except as required by law."

Industry Context

This joint venture positions Avant Technologies in the rapidly evolving biotech sector, specifically targeting diabetes treatment with cell-based therapies. Cell encapsulation technology, as provided by Austrianova, is a cutting-edge approach to protect and deliver living cells, offering potential for long-term therapeutic effects and reduced immune response. The diabetes market is vast and growing, with significant demand for innovative and more effective treatments beyond traditional insulin injections. This move aligns with a broader industry trend towards advanced biological and regenerative medicine solutions.

Comparison to Industry Standards

• The 50/50 joint venture structure is common in early-stage biotech collaborations, allowing for shared risk, expertise, and intellectual property.
• The initial funding commitment of $1.5 million for 18 months is a reasonable seed investment for a biotech startup, though significant additional capital will be required for clinical development, which is typical for the industry.
• The potential $8.5 million follow-up loan for clinical trials represents a substantial commitment, comparable to early-stage venture capital rounds for novel therapeutic development in the biotech sector.
• Austrianova's proprietary 'Cell-in-a-Box' technology for cell encapsulation is a competitive approach, similar to other companies exploring encapsulation for cell therapies (e.g., Sernova Corp. with its Cell Pouch for diabetes, ViaCyte/CRISPR Therapeutics with stem-cell derived islet cells in encapsulation devices). The success will depend on its clinical efficacy and safety compared to these and other emerging treatments.
• Austrianova's background, including 'more than 50 international peer-reviewed publications' and 'contracts from leading pharmaceutical and biotech companies,' suggests a strong scientific foundation, which is a positive indicator for a biotech partner and aligns with industry best practices for scientific rigor.

Management Changes

Corporate Governance

Related Party Transactions

• AVAI is providing initial capital of up to $1.5 million and has the option to provide an additional $8.5 million loan to Insulinova, a 50% owned joint venture.
• Austrianova is granting an exclusive license for its proprietary cell encapsulation technology to Insulinova.
• Austrianova will provide services (research and development, manufacture, and supply of product) to Insulinova, with costs invoiced to Insulinova.
• AVAI and Austrianova will co-manage the day-to-day operations of Insulinova, with associated costs invoiced to Insulinova.
• Price consideration for IP licenses, service agreements, manufacturing, invoices, and supply of the Insulinova Product will be payable to Austrianova or AVAI.

Stakeholder Impact

• Shareholders (AVAI): Potential for long-term value creation through participation in a promising biotech venture targeting diabetes, balanced by the investment risk of initial capital and potential future loans.
• Shareholders (Austrianova): Opportunity to commercialize proprietary technology through a funded joint venture, sharing in potential profits and leveraging AVAI's resources.
• Patients (Diabetes): Potential for new, innovative treatments for diabetes if the product development is successful, offering hope for improved health outcomes.
• Employees (Insulinova): Creation of new employment opportunities in a biotech startup focused on cutting-edge medical solutions.
• Regulatory Authorities: Will be involved in the extensive approval process for clinical trials and product registration, ensuring safety and efficacy.

Next Steps

• Formal establishment of Insulinova, Inc. within the next twelve months.
• AVAI to provide up to $1.5 million in capital and resources for Insulinova's operations for the next 18 months.
• Development of an Annual Plan by Insulinova's CEO, to be approved by the Board, no later than 45 days prior to the commencement of each fiscal year.
• Potential for AVAI to provide an additional $8.5 million loan for further development and clinical testing.
• Arranging additional funding from strategic investors as needed.
• Conducting research and development, manufacturing, and supply of the Insulinova Product.
• Pursuing clinical trials for several clinical conditions, regulatory work, and product registration in various jurisdictions.

Key Dates

Recommendation

The formation of Insulinova represents a significant strategic move into the high-potential diabetes treatment market using advanced cell encapsulation technology. This could be a long-term value driver for AVAI. However, the venture is in its very early stages, with the formal company establishment still pending and substantial future funding contingent on AVAI's discretion. The previous retraction of a similar agreement adds a layer of uncertainty. While the potential upside is considerable, the inherent risks of biotech development, the early stage of the venture, and the optionality of future funding warrant a 'hold' recommendation for now. Investors should monitor the formal establishment of Insulinova, progress in securing the follow-up financing, and initial R&D milestones before considering a stronger position.

Keywords

Joint Venture, Biotech, Diabetes Treatment, Cell Encapsulation, Insulinova, Avant Technologies, SGAustria, AVAI, Austrianova, Clinical Trials, Intellectual Property, Healthcare, Pharmaceutical, Nevada Corporation, Singaporean Company